"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 17 | 17 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 63 | 63 |
| 2006 | 1 | 58 | 59 |
| 2007 | 0 | 69 | 69 |
| 2008 | 1 | 80 | 81 |
| 2009 | 2 | 109 | 111 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 118 | 119 |
| 2012 | 2 | 89 | 91 |
| 2013 | 2 | 116 | 118 |
| 2014 | 0 | 131 | 131 |
| 2015 | 0 | 138 | 138 |
| 2016 | 0 | 151 | 151 |
| 2017 | 0 | 120 | 120 |
| 2018 | 0 | 132 | 132 |
| 2019 | 1 | 130 | 131 |
| 2020 | 0 | 121 | 121 |
| 2021 | 0 | 117 | 117 |
| 2022 | 0 | 40 | 40 |
| 2023 | 0 | 56 | 56 |
| 2024 | 0 | 100 | 100 |
| 2025 | 0 | 126 | 126 |
| 2026 | 0 | 42 | 42 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors. Signal Transduct Target Ther. 2026 Jun 05; 11(1).
-
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood. 2026 Jun 04; 147(23):2809-2820.
-
Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells. Cancer Immunol Res. 2026 Jun 02; 14(6):933-943.
-
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis. Cancer Lett. 2026 Sep 01; 655:218636.
-
Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer. Cancer Lett. 2026 Sep 01; 655:218591.
-
Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant. PLoS One. 2026; 21(5):e0349130.
-
Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy. J Control Release. 2026 Jul 10; 395:115004.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Lett. 2026 Aug 10; 653:218562.
-
Alprazolam Reduces Inflammatory Cytokine Production in Pancreatic Cancer-Associated Fibroblasts. Cancer Res Commun. 2026 May 01; 6(5):1048-1060.